Subs	titute for form 1449/PTO			Complete if Known		
				Application Number	09/724,319	
INFORMATION DISCLOSURE				Filing Date	November 27, 2000	
				First Named Inventor	Schenk, Dale B.	
SI	FATEMENT BY AF	PLI	CANI	Art Unit	1649	
	(Use as many sheets as no	cessar	y)	Examiner Name	Ballard, Kimberly	
Sheet	1	of	9	Attorney Docket Number	15270J-004743US	

Examiner	Cite	Document Number	U.S. PATENT DO Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1		MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	1215	Number Kind Code ^{2 (r/kneen)} 2009/0297511	12-03-2009	Schenk	
			09-01-2009	Basi et al.	
	1192	7,582,733		Black et al.	
	1216	2009/0155256	6-18-2009		
	1169	2009/0142270 A1	06-04-2009	Schroeter et al.	
	1210	2007/0072307 A1	03-29-2007	Godavarti et al.	
	1096	2007/0021454 A1	01-25-2007	Coburn et al.	
	1196	7,147,851 B1	12-12-2006	Ponath et al	
	1153	2006/0234912	10-16-2006	Wang et al.	
	1197	7,112,661 B1	09-26-2006	Miller	
	1154	2006/0182321	08-17-2006	Hu et al.	
	1155	2006/0121038	06-08-2006	Schenk et al.	
	1099	2006/0057701 A1	03-16-2006	Rosenthal et al.	
	1098	2005/0090648 A1	04-28-2005	Tsurushita et al.	
	1195	6,824,780 B1	11-30-2004	Devaux et al.	
	1101	2003/0054484 A1	03-20-2003	Fong et al.	
	1170	2003/0009104 A1	01-09-2003	Hyman et al.	
	1211	6,432,710 B1	08-13-2002	Boss, Jr. et al.	
	1116	6,057,098	05-02-2000	Buechler et al.	
	1131	6,015,662	01-18-2000	Hackett et al.	
	1209	5,910,427	06-08-1999	Mikayama	
-	1148	5,773.007	06-30-1998	Penney et al.	
	1147	5,723,130	03-03-1998	Hancock et al.	
	1168	5.620.844	04-15-1997	Neurath et al.	
	1160	5,472,693	12-05-1995	Gourlie et al.	

	U.S. PATENT APPLICATIONS							
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant			
ingais:	No.	Number Kind Code ^{2 (Ykozen)}	MM-DD-1111	Applicant of Cited Document	Figures Appear			
	1212	60/530.480	12-17-2003	Arumuqham				

Examiner	Date	
Signature	Considered	

"EXAMINED: Initial if reference consistency whether or not cliation is in conformance with MPEP 860. Data line through clastion in fine in conformance and not considered floating only of this flow mich must communication to applicant. * Applicant is unique citation designation number (polinos), * See Kind Coles of U.S. Patent Decuments at vow. vasta and or of MPEP 901 04. * Enter Office that Issued the document, by the two-letter code (MIPO Standard ST3.* * For Japanese patent documents. The indication of the year of the religion of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST3. * 16 if possible. * Applicant is to place a check mark here If English Indiagouge Translation to a statude.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	09/724,319	
INFORMATION DISCLOSURE				Filing Date	November 27, 2000	
INFORMATION DISCLOSURE				First Named Inventor	Schenk, Dale B.	
STATEMENT BY APPLICANT				Art Unit	1649	
	(Use as many sheets as necessary)			Examiner Name	Ballard, Kimberly	
Sheet	2	of	9	Attorney Docket Number	15270J-004743US	

				FOREIGN I	PATENT DOCL			
Examiner Initials*	No.1		atent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	1102	Country Code ³	Number ⁴ 1 690 547	Kind Code ⁵ (if known) A1	00.40.4000			Н
	1176	EP EP		A1	08-16-1998			H
	1175	EP	616 814	A1	03-21-1994	Dunlinehe De		H
	1175	WO	08/131298	A3	12-18-2008	Duplicate. Do	not print.	H
	1107	wo	08/131298	A2	10-30-2008			H
	1133	wo	06/042158	A	04-20-2006			Η
	1146	wo	05/035753	Α	04-21-2005			H
	1206	wo	04/016282	A1	2-26-2004	_		H
	1152	wo	01/78777	A2	10-25-2001			H
	1177	wo	97/40147	A1	10-30-1997			H
	1178	wo	97/37031	A1	10/09/1997			H
	1179	wo	97/36601	A1	10/09/1997			Ħ
	1180	wo	97/28816	A1	08-14-1997			H
	1173	wo	97/18855	A1	05-29-1997			Ħ
	1151	wo	96/39834	A1	12-19-1996			Ħ
	1181	wo	96/29421	A1	09-26-1996			Ħ
	1182	wo	96/14061	A1	05-17-1996			
	1183	wo	94/21288	A1	09-29-1994			
	1184	wo	94/16731	A1	08-04-1994			
	1185	wo	94/09823	A1	05-11-1994			
	1186	wo	92/15330	A1	09-17-1992			
	1187	wo	92/07944	A1	05-14-1992			
	1188	WO	92/05793	A1	04-16-1992			
	1189	WO	90/14837	A1	12-13-1990			
	1174	WO	90/14840	A1	12-13-1990			
	1190	WO	87/06838	A1	11-19-1987			
	1145	wo	87/02671	Α	05-07-1987			

Examiner Date Simplying Considered			
ogniture .	Signature	Considered	

EXAMINET, Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through classion of not in conformance and not considered include copy of this form with next communication to applicant. **Applicant's suiture citation designation number (opiniosa)** See Kind Codes of U.S. Patent Documents at https://www.uspto.gov or MPEP 901.04. **Enter Office that issued the document, by the two-letter code (WPO Standard ST3.**). **For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under VMPO Standard ST.** 16 if possible. **Applicant is to place a check mark here It English inappage Translation is statisticed.

Substitu	te for form 1449/PTO			(Complete if Known	
				Application Number	09/724,319	
INF	DRMATION DIS	SCLOS	URE	Filing Date	November 27, 2000	
STA	TEMENT BY A	PPLIC	ANT	First Named Inventor	Schenk, Dale B.	
				Art Unit	1649	
	(Use as many sheets as	necessary)		Examiner Name	Ballard, Kimberly	
Sheet	3	of	9	Attorney Docket Number	15270J-004743US	

Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	1156	ALLEN et al, "Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI Regimen for Metastatic Colon Caner," Arch. Neurol., 63(10): 1475- 1476 (2006), abstract only.	С				
	1120	ARMOUR et al., "Recombinant human IgG molecules lacking Fcy receptor I binding and monocyte triggering activates," J. Immunol, 29:2613-2624 (1999).					
	1117	AVIS, "Perenteral Preparations," Remington's Pharmaceutical Sciences, 17:1518-1519 (1985).					
	1191	BIEWENGA et al., "Cleavage of Protein A-binding IgA1 with IgA1 Protease From Streptococcus Sanguls," <u>Immunol Commun.</u> , 12(5):491-500 (1983), abstract only.	С				
	1207	BORRAS-CUESTA et al., "Engineering of Immunogenic Peptides by Co-Linear Synthesis of Determinants Recognized by B and T Cells," Eur. J. Immunol., 17:1213-1215 (1987)	С				
	1138	BRINKMAN, "Splice Variants as Cancer Biomarkers," Clinical Biochemistry, 37(7):584-594 (2004).					
	1204	BUTTINI et al., " β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease," <u>The Journal of Neuroscience</u> , 25(40):9096-9101 (2005).					
	1110	CHEN et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen," J. Mol. Biol., 293:865-881 (1999).					
	1142	CHOI et al., "A Generic Intron Increases Gene Expression in Transgenic Mice," Molecular and Cellular Biology, 11(6):3070-3074 (1991).	Г				
	1132	Corcoran et al., "Overexpression of hAPPswe Impairs Rewarded Alternation and Contextual Fear Conditioning in a Transgenic Mouse Model of Alzheimer's Disease," Learn Mem. 9(5):243-252:2000.					

	The Appropriate Control of the Contr
Signature	Considered
Examiner	Date

EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant surjuge citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for	or form 1449/PTO			0	Complete if Known	2000 B.
				Application Number	09/724,319	
INFO	RMATION DIS	SCLOS	URE	Filing Date	November 27, 2000	
STAT	EMENT BY A	PPLIC	ANT	First Named Inventor	Schenk, Dale B.	
				Art Unit	1649	
(Use as many sheets as	necessary)		Examiner Name	Ballard, Kimberly	
Sheet	4	of	9	Attorney Docket Number	15270J-004743US	

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1144	DATABASE Geneseq, "Nucleotide Sequence of a Variable Heavy Chain of IgG4," EBI Accession No. GSN:ADZ51216 (2005).	
	1100	Dialog/Derwent, Abstract of WPI Acc No: 1995-261292/199534: Novel monoclonal antibody against human high-affinity IgE receptor – and DNA fragment encoding the MAb, for the specific identification of human Fc-epsilon RI, Derwent WPI database (1995).	
	1194	Ecuadorian Search Report of 07/02/2009 for Ecuador Patent Application No. SP 03-4685.	
	1137	Extended European Search Report of 12/18/08 for European Application 05812436.6-1212.	
	1136	European Examination Report of 09/23/2008 for European Application 04776252.1-2405.	
	1130	European Examination Report as part of 12-08-2008 communication for European Application 04720353.4	
	1134	European Examination Report of 11/20/2008 for European Application 08011409.3	
	1150	Family and legal status of EP0613007, Inpadoc Search (2009).	
	1097	FRAGIONE et al., "Familial cerebral amyloid angiopathy related to stroke and dementia. <u>Amyloid.</u> 8(Suppl 1):38-42 (2001), abstract only.	
	1163	Genbank Accession number AAA69734, Schroeder et al., "Immunoglobulin heavy chain [Homo sapiens]", Anti-DNA immunoglobulin light chain IgG [Mus musculus], "07/11/95.	

Examine Signatur		Date Considered	
	1		

EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 609. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

"Applicant's unique clation designation number (options)." Applicant is unique clation designation number (options)." Applicant is unique clation designation number (options)." Applicant is unique clation designation number (options)."

Substitute	for form 1449/PTO			Complete if Known			
				Application Number	09/724,319		
INFO	RMATION	DISCLOS	URE	Filing Date	November 27, 2000		
STA	TEMENT E	Y APPLIC	ANT	First Named Inventor	Schenk, Dale B.		
				Art Unit	1649		
	(Use as many she	ets as necessary)		Examiner Name	Ballard, Kimberly		
Sheet	5	of	9	Attorney Docket Number	15270J-004743US		

xaminer Initials *	Cite No.1								
	1164	Genbank Accession number BAC01733, Akahori et al., "Immunoglobulin kappa light chain VLJ region [Homo sapiens]", 07/02/02.							
	1208	GHETIE et al., "CD4 Peptide-Protein Conjugates, But Not Recombinant Human CD4, Bind to Recombinant gp120 From the Human Immunodeficiency Virus in the Presence of Serum From AIDS Patients," Proc. Natl. Acad. Sci. 8:5690-5693 (1991).							
	1205	GOLDING et al., "Vaccine Strategies: Targeting Helper T Cell Responses," <u>Annals New York Academy of Sciences</u> , 31:126-137 (1995).							
	1118	HEZAREH et al., "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>Journal of Virology</u> , 24(75):12161-12168 (2001).							
	1200	HILLEN-MASKE et al., "Konichalcit", Rompp Chemie Lexilkon, 9 th edition, pg. 2322 (1990).							
	1193	HOGARTH, Fc Receptors Are Major Mediators of Antibody Based Inflammation in Autoimmunity," Current Opinion in Immunology, 14:798-802 (2002).							
	1127	JANEWAY et al., Immunobiology, 3 rd edition, pages 8:18-8:19 (1997).							
	1121	MANN et al., "Atypical Amyloid (ABeta) Deposition in the cerebellum in Alzheimer's Disease: An Immunohistochemical Study Using End-Specific ABeta Monoclonal Antibodies," <u>ACTA</u> Neuropathologica. 9:1647-653 (1996).							
1122 MANN et al., "Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene." The <u>American Journal of Pathology APR</u> , 4(148): 1257-1 (1996).									
	1157	57 MAVRAGANI et al., "A Case of Reversible Posterior Leucoencephalopathy Syndrome After Rityximab Infusion," Rheumatology, 43(11) 1450-1451 (2006).							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

STATEMENT BY APPLICANT (Use as many sheets as necessary) First Named Inventor Schenk, Dale B. Art Unit 1649 Examiner Name Ballard, Kimberly	Substitute for form 1449/PTO				Complete if Known			
STATEMENT BY APPLICANT First Named Inventor Schenk, Dale B. Art Unit 1649 Examiner Name Ballard, Kimberly					Application Number	09/724,319		
Art Unit 1649 (Use as many sheets as necessary) Art Unit 1649 Examiner Name Ballard, Kimberly	INFO	RMATION	DISCLOSU	JRE	Filing Date	November 27, 2000		
(Use as many sheets as necessary) Examiner Name Ballard, Kimberly	STATEMENT BY APPLICANT			NT	First Named Inventor	Schenk, Dale B.		
Ballard, Kiriberry					Art Unit	1649		
	(Use as many sheets as necessary)				Examiner Name	Ballard, Kimberly		
Sheet 6 of 9 Attorney Docket Number 15270J-004743U	Sheet	6	of	9	Attorney Docket Number	15270J-004743US		

Examiner Initials *	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	1198	MITCHELL et al, "Prevention of Intracerebral Hemorrhage," Current Drug Targets, 8(7):832-838 (2007).						
	1201	MUTSCHLER et al., "Arzneimittel-Wirkungen, Lehrbuch der Pharmakologie und Taxiklogie," Wissenschfliche Verlagsgesellschaft mbH Stuttgart, 6 th edition, pgs. 651-656 (1991), (German Article).						
-	1139	MYERS et. al., "Targeting Immune Effector Molecules to Human Tumor Cells Through Genetic Delivery of 5T4-Specific SCFV Fusion Proteins," Cancer Gene Therapy, 9(11):884- 896 (2002).						
 PADLAN et al., "Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL Fab-lysozyme Complex, Immunology, 86:5938-5942 (1989). PANGALOS et al., "Disease Modifying Strategies for the Treatment of Alzheimer's Disease Targeted at Modulating Levels of β-amyloid Peptide," Biochemical Society Transactions, 33(4):653-568 (2005). 								
						1108	PASCALIS et al., "Grafting of 'Abbreviated" Complementarity-Determining Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," <u>The Journal Immunology</u> , 169:3076-3084 (2002).	С
	1158	PCT Written Opinion of 12/22/2008 for application PCT/US2008/80370.						
PCT International Preliminary Report on Patentability (Chapter I) of 10/20/2009 with Writte Opinion of 10/03/2008 for application PCT/US2008/060926.								
	1159 PCT Search Report of 01/22/2009 for application PCT/US2008/80370.							

Signature	Considered
EXAMINER: Initial if reference considered, whether or not citation is in confo	mance with MPEP 609, Draw line through citation if not in conformance and

Exhaunces, militar include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449/PTO			Complete if Known			
				Application Number	09/724,319		
INFO	RMATION	DISCLOS	URE	Filing Date	November 27, 2000		
STA	TEMENT E	Y APPLIC	ANT	First Named Inventor	Schenk, Dale B.		
				Art Unit	1649		
	(Use as many she	ets as necessary)		Examiner Name	Ballard, Kimberly		
Sheet	7	of	9	Attorney Docket Number	15270J-004743US		

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²
		number(s), publisher, city and/or country where published.	
	1213	PCT Search Report of 10/09/2008 for application PCT/US2008/060926.	
	1172	PRADA et al., "Antibody-Mediated Clearance of Amyloid-β Peptide From Cerebral Amyloid Angiopathy Revealed by quantitative in Vivo Imaging," Journal of Neuroscience, 27(8):1973- 1980 (2007).	
	1149	QU et al., " $A\beta_{42}$ gene Vaccine Prevents $A\beta_{42}$ deposition in brain of Double Trangenic Mice," <u>J. Neurological Sciences</u> , 260.204-213 (2007).	
	1199	RIECHMANN et al., "Reshaping Human Antibodies for Therapy," Nature, 332:323-327 (1988).	
	1141	ROBBINS et al., "The Intronic Region of an Incompletely Spliced gp100 Gene Transcript Encodes an Epitope Recognized by Melanoma-Reactive Tumor-Infiltrating Lymphocytes," Journal of Immunology, 159(1):303-308 (1997).	
	1202	SAIDO et al., "Autolytic Transition of μ-Calpain Upon Activation as Resolved by Antibodies Distinguishing Between the Pre- and Post-Autolysis Forms," J. Biochem., 111:81-86 (1992).	
	1123	SCHMIDT et al., "Monoclonal Antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains," <u>The American Journal of Pathology</u> , (1651):88-80 (1997).	
	1165	SCHROEDER et al., "Preferential Utilization of Conserved Immunoglobulin Heavy Chain Variable Gene Segments During Human Fetal Life," mmunology , 87:6146-6150 (1990).	
	1140	SEABROOK et al., "Species-specific Immune response to Immunization with Human Versus rodent Abeta Peptide," Neurobiology of Aging, 25(9) 1141-1151 (2004)	
	1119	Shepherd et al., "The design of the humanized antibody," Monocolonal Antibodies: A Practical Approach 58-66 (2000)	

Examiner Signature		Date Considered		
EXAMINER: I	nitial if reference considered, whether or not citation is in conformance with MPEP	609. Draw line th	rough citation if not in conformance and	

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449/PTO			Complete if Known			
				Application Number	09/724,319		
INFO	RMATION DI	SCLOS	URE	Filing Date	November 27, 2000		
STA	TEMENT BY	APPLIC	ANT	First Named Inventor	Schenk, Dale B.		
				Art Unit	1649		
	(Use as many sheets as	necessary)		Examiner Name	Ballard, Kimberly		
Sheet	8	of	9	Attorney Docket Number	15270J-004743US		

				1		
Examiner Initials *	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	1104	SIDHU, "Page display in pharmaceutical biotechnology," <u>Current Opinion in Biotechnology</u> , 11:610-616 (2000).				
	1105	SMITH et al., "Phage Display," Chemical Reviews , <a <u="" a="" approach="" href="American Chemical Society, 97(2):391-410 (1997).</td><td></td><td></td></tr><tr><td></td><td>1203</td><td>SOOD et al., " modern="" peptides:="" synthetic="" to="" vaccination,"="">Indian Journal of Experimental Biology, 34:849-861 (1998).				
	1128	STUDNICKA et al., "Human-engineered monocilnal antibodies retain full specific binding activity by preserving non-CDR complementary-modullating resudes," Protein Eng., 7(6):805-814 (1994), Abstract only.	in full specific binding les," Protein Eng.,			
	1124 TAMAOKAet al., "Antibodies to amyloid beta protein (A beta) crossreact with glyceraldehyde- 3-phosphate dehyrogenase (GAPDH)," Neurobiology of Aging, 3(17):405-414 (1996).					
	1162	TRANG et al., "Pharmacokinetics of a Mouse/Human Chimeric Monocional Antibody (C-17-1A) in Metastatic Adentarchroma Patients," Pharmaceutical Research 7(6):587-592 (1990).		Duplicate reference		
	1112	U.S. Application No. 09/316,387, Office Action mailed 09/10/2007.				
	1113	U.S. Application No. 09/316,387, Response to 06-20-2005 Office Action filed 12-20-2005.				
	1114	U.S. Application No. 09/316,387, Declaration of Solomon, Hrncic, and Wall under 37 C.F.R. § 1.131 filed 03-06-2006.				
	1115 U.S. Application No. 09/316,387, Office Action mailed 06/20/2005.					
	1109	Vajdos et al., "Comprehensive Functional Maps of the Antigen-binging site of an Anti_ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis." J. Mol. Biol., 320:415-428 (2002).				
Examiner Signature		Date Considered		j		

"EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant "Applicants using colation designation number (optional", Applicants into pi face a check mark here if English language Translation is attached.

Subs	tute for forn	n 1449/PTO			Complete if Known			
					Application Number	09/724,319		
IN	ORM	ATION DIS	CLOS	URE	Filing Date	November 27, 2000		
STATEMENT BY APPLICANT					First Named Inventor	Schenk, Dale B.		
					Art Unit	1649		
(Use as many sheets as necessary)					Examiner Name	Ballard, Kimberly		
Shee	9		of	9	Attorney Docket Number	15270J-004743US		

		NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials *	Cite No.1		
	1143	WARD et al., "Spontaneous Deletions In IG Heavy Chain Genes Flanking Sequences Influence Splice Site Selection Nucleic Acids Research," 19(23): 6475-6480 (1991).	
	1161	Wikipedia entry for Antibody, retrieved April 27, 2009 from http://en.wikipedia.org/wiki/Antibody.	
	1106	WILSON et al., "Phage display: applications, innovations, and issues in phage and host biology," Can. J. Microbiol. 44:313-329 (1998).	
	1111	WU et al., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," <u>J. Mol. Biol.</u> , 294:151-162 (1999).	
	1125	YANAGISAWA K et al., "Amyloid BETA-protein (Alpha-Beta) associated with lipid molecules: immunoreactivity distinct from that of soluble Alpha-Beta," FEBS Letters, 1(420): 43-45 (1997).	
	1126	YANG et al., "Monoclonal Antibody to the C-terminus of Beta-Amyloid," Neuroreport, 16(5):2117-2120 (1994).	

Examiner Signature	/Kimberly Ballard/	Date Considered	12/15/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.